You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Apatinib

Showing 1 - 25 of 467
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Osteosarcoma Trial (Tucidinostat, Apatinib)

Not yet recruiting
  • Osteosarcoma
  • Tucidinostat, Apatinib
  • (no location specified)
Nov 5, 2023

Relapsed Ovarian Cancer Trial (Fluzoparib, Apatinib)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Oct 7, 2023

Acral Melanoma Trial (camrelizumab+apatinib+TMZ, camrelizumab+apatinib, camrelizumab)

Not yet recruiting
  • Acral Melanoma
  • (no location specified)
Mar 16, 2023

Chordoma, Chemo Effect Trial in Beijing (camrelizumab and apatinib)

Recruiting
  • Chordoma
  • Chemotherapy Effect
  • camrelizumab and apatinib
  • Beijing, Beijing, China
    BEIJING
Nov 14, 2023

Ovarian Cancer Recurrent Trial (Fluzopril Combined With Apatinib)

Not yet recruiting
  • Ovarian Cancer Recurrent
  • Fluzopril Combined With Apatinib
  • (no location specified)
Oct 22, 2023

NSCLC, NSCLC Trial in Guangzhou (Apatinib + Fluzoparib, Apatinib + Fluzoparib + Adebrelimab)

Not yet recruiting
  • NSCLC
  • Non-small Cell Lung Cancer
  • Apatinib + Fluzoparib
  • Apatinib + Fluzoparib + Adebrelimab
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Jun 27, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Advanced Hepatocellular Carcinoma Trial in Guangzhou (adebrelimab, camrelizumab plus apatinib)

Not yet recruiting
  • Advanced Hepatocellular Carcinoma
  • adebrelimab, camrelizumab plus apatinib
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital
Jun 21, 2023

Esophageal Cancer by AJCC V8 Stage Trial in Zhengzhou (Camrelizumab+Apatinib+Chemotherapy?Camrelizumab+Apatinib,

Recruiting
  • Esophageal Cancer by AJCC V8 Stage
  • Zhengzhou, Henan, China
    The First Affiliated Hospital of Zhengzhou University
Feb 12, 2023

Locally Advanced Biliary Tract Cancer, Metastatic Biliary Tract Cancer Trial in Guangzhou (Camrelizumab and Apatinib Plus GP)

Not yet recruiting
  • Locally Advanced Biliary Tract Cancer
  • Metastatic Biliary Tract Cancer
  • Camrelizumab and Apatinib Plus GP
  • Guangzhou, Guangdong, China
    Cancer center of SunYat-sen University
Feb 15, 2023

Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Guangzhou, Guangdong, China
    Department of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023

Gastric Cancer Trial in Tianjin (AK104, Apatinib, Paclitaxel)

Recruiting
  • Gastric Cancer
  • Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
May 7, 2023

Gastric Cancer Trial in Beijing (Apatinib, Oxaliplatin, S1)

Recruiting
  • Gastric Cancer
  • Apatinib
  • +2 more
  • Beijing, Beijing, China
    Beijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023

Gastrointestinal Stromal Tumors Trial in Changsha (Apatinib Mesylate, Sunitinib, Imatinib dosage, Dasatinib, Reveratinib)

Recruiting
  • Gastrointestinal Stromal Tumors
  • Apatinib Mesylate
  • Sunitinib, Imatinib dosage, Dasatinib, Reveratinib
  • Changsha, Hunan, China
    Xiangya Hospital, Central South University
Mar 1, 2023

Hepatocellular Carcinoma Trial in Jinan (Camrelizumab)

Recruiting
  • Hepatocellular Carcinoma
  • Jinan, Shandong, China
    Shandong Cancer Hospital and Institute
Nov 16, 2022

Macrotrabecular Massive Hepatocellular Carcinoma Trial in Wuhan (HAIC, Camrelizumab plus Apatinib)

Recruiting
  • Macrotrabecular Massive Hepatocellular Carcinoma
  • HAIC
  • Camrelizumab plus Apatinib
  • Wuhan, Hubei, China
    Hepatic Surgery Center, Tongji Hospital, Tongji Medical College,
May 1, 2023

Melanoma, Acral Melanoma, Temozolomide Trial (Camrelizumab)

Not yet recruiting
  • Melanoma
  • +6 more
  • (no location specified)
Aug 21, 2022

Breast Cancer Metastatic Cancer Trial in Shanghai (Apatinib, Dalpiciclib, Fulvestrant/AI)

Recruiting
  • Breast Cancer Metastatic Cancer
  • Apatinib
  • +2 more
  • Shanghai, Shanghai, China
    Breast cancer institute of Fudan University Cancer Hospital
Feb 26, 2023

Gestational Trophoblastic Neoplasia Trial in Beijing (Camrelizumab plus apatinib CohortA, Camrelizumab plus apatinib Cohort B)

Recruiting
  • Gestational Trophoblastic Neoplasia
  • Camrelizumab plus apatinib CohortA
  • Camrelizumab plus apatinib Cohort B
  • Beijing, China
    Peking Union Medical College Hospital
Jul 7, 2022

Immunotherapy, Gastrict Cancer Trial in Fuzhou (Tislelizumab, Apatinib Mesylate, oxaliplatin)

Recruiting
  • Immunotherapy
  • Gastrict Cancer
  • Fuzhou, China
    Fujian cancer hospital
Jan 17, 2023

Cholangiocarcinoma Trial (Carrilizumab, Albumin-bound paclitaxel, Apatinib)

Not yet recruiting
  • Cholangiocarcinoma
  • (no location specified)
Dec 9, 2022

Colon Cancer, Neoadjuvant Therapy Trial in Hangzhou (Camrelizumab , apatinib and chemo)

Recruiting
  • Colon Cancer
  • Neoadjuvant Therapy
  • Camrelizumab , apatinib and chemotherapy
  • Hangzhou, Zhejiang, China
    First affiliated hospital, Zhejiang University
Jan 27, 2023

Sarcoma Trial in Shanghai (MASCT-I,PD1 Antibody,Apatinib)

Active, not recruiting
  • Sarcoma
  • MASCT-I,PD1 Antibody,Apatinib
  • Shanghai, Shanghai, China
    Shanghai Sixth People's Hospital
Nov 22, 2022

Immunotherapy Gastrict Cancer Trial (Tislelizumab, apatinib, oxaliplatin)

Not yet recruiting
  • Immunotherapy Gastrict Cancer
  • (no location specified)
Jan 17, 2023

Hepatocellular Carcinoma, Immunotherapy, Preoperative Trial in Nanjing (Camrelizumab, Apatinib Mesylate, Postoperative TACE

Recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Nov 6, 2022